Alterations in copy numbers of paclitaxel-metabolizing CYPs (CYP2C8, CYP3A4) were aimed to be determined in primary lung adenocarcinoma samples prior to therapy. The gene discussed is CYP3A4; the disease is lung adenocarcinoma.